Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. 2007

Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
Laboratory of Molecular Pharmacology, Bldg 37, Rm 5068, National Institutes of Health, Bethesda, MD 20892-4255. pommier@nih.gov.

Chk2 is a protein kinase involved in the ATM-dependent checkpoint pathway (http://discover.nci.nih.gov/mim). This pathway is activated by genomic instability and DNA damage and results in either cell cycle arrest, to allow DNA repair to occur, or cell death (apoptosis). Chk2 is activated by ATM-mediated phosphorylation and autophosphorylation and in turn phosphorylates its downstream targets (Cdc25A, Cdc25C, BRCA1, p53, Hdmx, E2F1, PP2A, and PML). Inhibition of Chk2 has been proposed to sensitize p53-deficient cells as well as protect normal tissue after exposure to DNA-damaging agents. We have developed a drug-screening program for specific Chk2 inhibitors using a fluorescence polarization assay, immobilized metal ion affinity-based fluorescence polarization (IMAP). This assay detects the degree of phosphorylation of a fluorescently linked substrate by Chk2. From a screen of over 100,000 compounds from the NCI Developmental Therapeutics Program, we identified a bis-guanylhydrazone [4,4'-diacetyldiphenylureabis(guanylhydrazone); NSC 109555] as a lead compound. In vitro data show the specific inhibition of Chk2 kinase activity by NSC 109555 using in vitro kinase assays and kinase-profiling experiments. NSC 109555 was shown to be a competitive inhibitor of Chk2 with respect to ATP, which was supported by docking of NSC 109555 into the ATP binding pocket of the Chk2 catalytic domain. The potency of NSC 109555 was comparable with that of other known Chk2 inhibitors, such as debromohymenialdisine and 2-arylbenzimidazole. These data define a novel chemotype for the development of potent and selective inhibitors of Chk2. This class of drugs may ultimately be useful in combination with current DNA-damaging agents used in the clinic.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002224 Carbanilides Compounds consisting of two phenyl groups joined by a urea. Derivatives may be used as ANTIPARASITIC AGENTS. Diphenylurea Compounds,Compounds, Diphenylurea
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D016231 Fluorescence Polarization Immunoassay Fluoroimmunoassay where detection of the hapten-antibody reaction is based on measurement of the increased polarization of fluorescence-labeled hapten when it is combined with antibody. The assay is very useful for the measurement of small haptenic antigens such as drugs at low concentrations. Immunoassay, Fluorescence Polarization,Polarization Fluoroimmunoassay,Fluorescence Polarization Immunoassays,Fluoroimmunoassay, Polarization,Fluoroimmunoassays, Polarization,Immunoassays, Fluorescence Polarization,Polarization Fluoroimmunoassays,Polarization Immunoassay, Fluorescence,Polarization Immunoassays, Fluorescence
D017346 Protein Serine-Threonine Kinases A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors. Protein-Serine-Threonine Kinases,Serine-Threonine Protein Kinase,Serine-Threonine Protein Kinases,Protein-Serine Kinase,Protein-Serine-Threonine Kinase,Protein-Threonine Kinase,Serine Kinase,Serine-Threonine Kinase,Serine-Threonine Kinases,Threonine Kinase,Kinase, Protein-Serine,Kinase, Protein-Serine-Threonine,Kinase, Protein-Threonine,Kinase, Serine-Threonine,Kinases, Protein Serine-Threonine,Kinases, Protein-Serine-Threonine,Kinases, Serine-Threonine,Protein Kinase, Serine-Threonine,Protein Kinases, Serine-Threonine,Protein Serine Kinase,Protein Serine Threonine Kinase,Protein Serine Threonine Kinases,Protein Threonine Kinase,Serine Threonine Kinase,Serine Threonine Kinases,Serine Threonine Protein Kinase,Serine Threonine Protein Kinases
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D020134 Catalytic Domain The region of an enzyme that interacts with its substrate to cause the enzymatic reaction. Active Site,Catalytic Core,Catalytic Region,Catalytic Site,Catalytic Subunit,Reactive Site,Active Sites,Catalytic Cores,Catalytic Domains,Catalytic Regions,Catalytic Sites,Catalytic Subunits,Core, Catalytic,Cores, Catalytic,Domain, Catalytic,Domains, Catalytic,Reactive Sites,Region, Catalytic,Regions, Catalytic,Site, Active,Site, Catalytic,Site, Reactive,Sites, Active,Sites, Catalytic,Sites, Reactive,Subunit, Catalytic,Subunits, Catalytic
D064447 Checkpoint Kinase 2 Enzyme activated in response to DNA DAMAGE involved in cell cycle arrest. The gene is located on the long (q) arm of chromosome 22 at position 12.1. In humans it is encoded by the CHEK2 gene. CDS1 Kinase,CHEK2 Kinase,Checkpoint-Like Protein CHK2,Chk2 Protein Kinase,LFS2 Protein Kinase,PP1425 Protein Kinase,Serine Threonine Protein Kinase Chk2,Serine-Threonine-Protein Kinase CHK2,hCHK2 Kinase,CHK2, Checkpoint-Like Protein,CHK2, Serine-Threonine-Protein Kinase,Checkpoint Like Protein CHK2,Kinase 2, Checkpoint,Kinase CHK2, Serine-Threonine-Protein,Kinase, CDS1,Kinase, CHEK2,Kinase, Chk2 Protein,Kinase, LFS2 Protein,Kinase, PP1425 Protein,Kinase, hCHK2,Protein CHK2, Checkpoint-Like,Protein Kinase, Chk2,Protein Kinase, LFS2,Protein Kinase, PP1425

Related Publications

Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
February 1976, Chemico-biological interactions,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
September 1973, Cancer research,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
August 1973, Journal of medicinal chemistry,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
October 1971, Cancer research,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
October 1972, Biochemical pharmacology,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
January 1987, Biochemical and biophysical research communications,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
August 1970, Cancer research,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
January 1981, Cancer chemotherapy and pharmacology,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
January 1983, Methods in enzymology,
Andrew G Jobson, and John H Cardellina, and Dominic Scudiero, and Sudhir Kondapaka, and Hongliang Zhang, and Hijoo Kim, and Robert Shoemaker, and Yves Pommier
February 1968, Cancer research,
Copied contents to your clipboard!